- Report
- March 2026
- 157 Pages
Global
From €3500EUR$4,211USD£3,111GBP
- Report
- July 2026
- 130 Pages
Global
From €4318EUR$4,850USD£3,708GBP
- Report
- October 2025
- 87 Pages
Global
From €4007EUR$4,500USD£3,441GBP
- Report
- May 2026
- 150 Pages
United States
From €4318EUR$4,850USD£3,708GBP
- Report
- March 2026
- 150 Pages
United States
From €4318EUR$4,850USD£3,708GBP
- Report
- March 2026
- 248 Pages
United States
From €4318EUR$4,850USD£3,708GBP
- Report
- February 2026
- 240 Pages
United States
From €4318EUR$4,850USD£3,708GBP
- Report
- January 2024
- 348 Pages
Global
From €5243EUR$6,095USD£4,350GBP
- Report
- December 2022
- 354 Pages
Global
From €4761EUR$5,534USD£3,950GBP
- Report
- March 2026
- 282 Pages
From €3695EUR$4,150USD£3,173GBP
- Report
- May 2025
- 120 Pages
Global
From €5298EUR$5,950USD£4,549GBP
- Report
- July 2023
- 74 Pages
Global
From €5298EUR$5,950USD£4,549GBP
- Report
- August 2025
- 100 Pages
Global
From €5298EUR$5,950USD£4,549GBP
- Report
- August 2025
- 180 Pages
Global
From €3156EUR$3,545USD£2,710GBP
€3507EUR$3,939USD£3,012GBP
- Report
- August 2025
- 199 Pages
Global
From €3156EUR$3,545USD£2,710GBP
€3507EUR$3,939USD£3,012GBP
- Report
- August 2025
- 199 Pages
Global
From €3156EUR$3,545USD£2,710GBP
€3507EUR$3,939USD£3,012GBP
- Report
- August 2025
- 186 Pages
Global
From €3156EUR$3,545USD£2,710GBP
€3507EUR$3,939USD£3,012GBP
- Report
- August 2025
- 180 Pages
Global
From €3156EUR$3,545USD£2,710GBP
€3507EUR$3,939USD£3,012GBP
- Report
- August 2025
- 197 Pages
Global
From €3156EUR$3,545USD£2,710GBP
€3507EUR$3,939USD£3,012GBP
- Report
- August 2025
- 198 Pages
Global
From €3156EUR$3,545USD£2,710GBP
€3507EUR$3,939USD£3,012GBP

The Dry Powder Inhaler (DPI) market is a segment of the respiratory drugs market. It is a device used to deliver medication to the lungs in the form of a dry powder. It is a convenient and efficient way to deliver medication to the lungs, as it does not require the use of a propellant gas. DPIs are used to treat a variety of respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. They are also used to deliver vaccines and other medications.
DPIs are becoming increasingly popular due to their convenience and effectiveness. They are also cost-effective, as they require fewer components than other inhalers. Additionally, DPIs are easy to use and can be used by patients of all ages.
Several companies are involved in the DPI market, including GlaxoSmithKline, Boehringer Ingelheim, Novartis, Merck, and AstraZeneca. These companies are involved in the development, manufacture, and marketing of DPIs. Show Less Read more